ERCC1 and squamous cell carcinoma: For example, in a study by Jun et al., patients with locally advanced squamous cell carcinoma of the head and neck treated with cisplatin-based concurrent chemoradiotherapy were collected for analysis of 3-year progression-free survival and overall survival rates and ERCC1 expression [14], the results suggested that ERCC1 expression might be a useful predictive marker of locally advanced squamous cell carcinoma of the head and neck in patients treated with cisplatin-based CRT.